Health Care · Biotechnology

Incyte Corporation INCY

$118.87+1.20 (+1.02%)delayed quote · as of 2026-07-28 12:53 UTC

Open INCY in the workspaceCharts, statements, and the evidence behind every figure — free to start.

Market cap

$23.7B

Previous close

$117.67

Volume

2.7M

52-week range

$71.00 – $120.71

Verdictconfidence 81% · high

Strong across every dimension we score.

5 of 5 dimensions score well.

Value753/4 checks

Growth1004/4 checks

Quality753/4 checks

Health1003/3 checks

Momentum1005/5 checks

Fair-value estimate $134.32 per share (2-stage FCF · individual beta · 10Y Rf 4.7%) — the price sits 12% below it.

Every check behind these scores — with its numbers, source, and evidence link — is in the workspace. Free account required.

Key ratioslatest filing FY 2025

Value

P/E TTM

16.8

P/E FWD

13.2

EV/EBITDA TTM

12.8

PEG

1.31

FCF yield

—

Growth

Revenue 3y

+14.8%/yr

Revenue YoY

+21.2%

Expected EPS

+27.3%

Quality

Piotroski F

7 / 9

ROIC

ALAN GLOBAL INTELLIGENCE · alanglobalintelligence.comquote as of 2026-07-28 12:53 UTC · fundamentals FY 2025 · SEC EDGAR

Verdict

Reading INCY’s filed statements…

Continue with INCY in ALAN

Full evidence trail, financial statements back a decade, valuation history, charts, and alerts.

Open in the workspace Create free account

For information and research only. Not investment advice. ALAN does not place trades or execute orders. Figures come from the sources shown and can lag the market; verify independently before making decisions. Past performance is not predictive of future results.